Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Other Non Operating Income (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Other Non Operating Income for 7 consecutive years, with -$52.4 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 40.7% to -$52.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$73.6 million through Dec 2025, down 165.0% year-over-year, with the annual reading at -$21.2 million for FY2025, 20.44% up from the prior year.
  • Other Non Operating Income hit -$52.4 million in Q4 2025 for BridgeBio Pharma, down from -$21.2 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $28.3 million in Q4 2021 to a low of -$52.4 million in Q4 2025.
  • Historically, Other Non Operating Income has averaged -$3.2 million across 5 years, with a median of $1.5 million in 2023.
  • Biggest YoY gain for Other Non Operating Income was 1116.46% in 2021; the steepest drop was 7700.0% in 2021.
  • Year by year, Other Non Operating Income stood at $28.3 million in 2021, then crashed by 57.36% to $12.1 million in 2022, then surged by 80.58% to $21.8 million in 2023, then plummeted by 270.99% to -$37.2 million in 2024, then plummeted by 40.7% to -$52.4 million in 2025.
  • Business Quant data shows Other Non Operating Income for BBIO at -$52.4 million in Q4 2025, -$21.2 million in Q1 2025, and -$37.2 million in Q4 2024.